Form 4: Lyell Immunopharma: Insider Sells Shares for Commission

Innovative Cellular Therapeutics Holdings Ltd, a director and 10% owner of Lyell Immunopharma, Inc., reported a transaction involving the transfer of 66,500 common shares.

Summary

• Innovative Cellular Therapeutics Holdings Ltd, a director and 10% owner of Lyell Immunopharma, Inc., transferred 66,500 shares of common stock.
• This transfer was made as a broker commission to LifeSci Advisors, LLC in connection with an Upfront Payment related to a License Agreement dated November 6, 2025.
• The transaction involved no cash consideration for the reporting person.
• Following this transaction, the reporting person beneficially owns 2,933,500 shares of common stock, down from 3,000,000 shares prior to the transfer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard disclosure of a non-cash transaction for services rendered rather than a sale of stock for personal gain or a significant acquisition.

Negatives

• A director and 10% owner transferred a significant number of shares (66,500), reducing their direct beneficial ownership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Management Comments

• The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
• Reflects 3,000,000 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 66,500 shares transferred.
• All shares are held directly and registered in the name of the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and major shareholders. This specific filing details a non-cash transfer for services, which is a common practice.

Related Party Transactions

• Transfer of 66,500 common shares by Innovative Cellular Therapeutics Holdings Ltd (a director and 10% owner) to LifeSci Advisors, LLC as broker commission.

Stakeholder Impact

• Shareholders: The filing provides transparency into insider holdings, with a reduction in direct beneficial ownership by a significant insider, though for a non-cash consideration.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Lyell Immunopharma, Innovative Cellular Therapeutics Holdings Ltd, Common Stock, Broker Commission, License Agreement